Clinical Trials Logo

NSCLC Stage IV clinical trials

View clinical trials related to NSCLC Stage IV.

Filter by:

NCT ID: NCT04507217 Completed - Brain Metastases Clinical Trials

Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC

Start date: September 15, 2020
Phase: Phase 2
Study type: Interventional

This is a phase II, Open-Label, Multicenter, Prospective Clinical Study to Investigate the Efficacy and Safety of Tislelizumab Combined with Pemetrexed/ Carboplatin in Patients with Brain Metastases of Non-squamous Non-small Cell Lung Cancer. The primary end point is PFS, and secondary endpoint is ORR, OS, DoR and Neurocognitive impairment. during the study, the exploratory objectives including (1) PD-L1 expression, TMB, and other potential predictive biomarkers, correlated with response to treatment (2) Progression-free survival based on intracranial response (iPFS) according to RECIST 1.1 and RANO-BM

NCT ID: NCT04492969 Not yet recruiting - NSCLC Stage IV Clinical Trials

Prospective Observation of Failure Patterns in NSCLC Treated With ICIs

Start date: September 1, 2020
Phase:
Study type: Observational [Patient Registry]

By prospectively observing the time to the best therapeutic effect of non-small cell lung cancer after ICI treatment, the characteristics of lesion distribution when the best therapeutic effect is reached, and the phenotype of disease progression after ICI treatment response, the investigators intended to explore the failure pattern of NSCLC after the once effective ICI treatment. The investigators also aim to evaluate the feasibility and clinical value of radiotherapy for the treatment of oligo-progressive lesions after ICI.

NCT ID: NCT04467801 Recruiting - NSCLC Stage IV Clinical Trials

Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy

Ipat-Lung
Start date: September 14, 2021
Phase: Phase 2
Study type: Interventional

For metastatic/advanced NSCLC patients who do not have targetable mutations, either immunotherapy targeting the programmed death-1 and its ligand (PD-1/L1) pathway alone or in combination with platinum doublet chemotherapy is now a standard of care. However, still about half of the patients do not benefit due to treatment resistance. It is therefore critically important to find novel therapies and combinations to benefit patients who have failed or are intolerant to 1st line immunotherapy. This study hypothesizes that ipatasertib in combination with taxane (e.g. docetaxel) can be an effective strategy. Ipatasertib is a novel adenosine triphosphate (ATP)-competitive inhibitor that has demonstrated robust and selective targeting of protein kinase B (PKB, also known as AKT) in cancer patients. Importantly, evidence from preclinical studies has demonstrated that AKT inhibitors (e.g. ipatasertib) can enhance the therapeutic effect of chemotherapy as well as immunotherapy via modulating Phosphatidylinositol 3-kinase (PI3'K)-AKT activity.

NCT ID: NCT04467723 Recruiting - NSCLC Stage IV Clinical Trials

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

Start date: May 18, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to see if adding pirfenidone to atezolizumab will increase anti tumor activity and reduce treatment resistance in stage 4 and recurrent non- small cell lung cancer participants.

NCT ID: NCT04364620 Completed - NSCLC Stage IV Clinical Trials

AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)

Start date: February 23, 2021
Phase: Phase 2
Study type: Interventional

This Phase II study will recruit 40 metastatic non-small cell lung cancer patients who failed treatment with a platinum-containing doublet treatment and an anti-PD1 or PD-L1 immune checkpoint antibody, administered simultaneously or sequentially. All recruited patients will receive AB-16B5 at a dose of 12 mg/kg once weekly combined with docetaxel at a dose of 75 mg/m2 once every 3 weeks.

NCT ID: NCT04306094 Recruiting - NSCLC Stage IV Clinical Trials

Factors Determining the Prognosis in NSCLC Stage IV

LUPROG
Start date: November 1, 2017
Phase:
Study type: Observational [Patient Registry]

This study is a cohort study with patients with advanced NSCLC. Patients will answer questionnaires about symptoms and quality of life and will be submitted to physical and blood tests, and computer tomography. The aim of this study is to estimate prognostic factors predicting survival to 3 months in patients with advanced NSCLC.

NCT ID: NCT04291092 Recruiting - Brain Metastases Clinical Trials

Camrelizumab Combined With Local Treatment in NSCLC Patients With BM

Start date: January 1, 2020
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of Camrelizumab Combined with Chemotherapy and Local Treatment in non-small cell lung cancer with brain metastases.

NCT ID: NCT04284202 Not yet recruiting - NSCLC Stage IV Clinical Trials

PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC

Start date: March 1, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evalute the efficacy and safety of PD-1 antibody combined with Dasatinib as third-line therapy for NSCLC patients with ARID1A mutation until disease progression or intolerable toxicity or patients withdrawal of consent. The target sample size is 30+individuals. The primary endpoint of this study is PFS、ORR、OS and the secondary endpoint is toxicity.

NCT ID: NCT04223596 Active, not recruiting - Lung Cancer Clinical Trials

Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients

CUBIK
Start date: May 4, 2020
Phase: Phase 2
Study type: Interventional

This is an open-label, non-randomised, phase II, exploratory, multi-country and multi-centre clinical trial. Chemotherapy-naïve patients with EML4-ALK rearrangement and with locally advanced or metastatic non-small cell lung cancer patients will be selected. Patients enrolled in the study will receive brigatinib 90mg for the first 7 days (D 1-7 at cycle 1) and then 180mg daily thereafter for QW4 cycles of duration (28 days ±3days). Brigatinib will be administered until progression disease, unacceptable toxicity, patient or physician decision to discontinue or death. Brigatinib may continue beyond disease progression per RECIST v1.1 until loss of clinical benefit, unacceptable toxicity, patient or physician decision to discontinue, or death as per SmPC recommendations. Patient accrual is expected to be completed within 1.5 years excluding a run-in-period of 4-6 months. Treatment and follow-up are expected to extend the study duration to a total of 5 years. Patients will be followed for 1 year after the end of treatment independently of the cause of end of treatment. The study will end once survival follow-up has concluded. The trial will end with the preparation of the final report, scheduled for 5.5 years after the inclusion of the first patient approximately.

NCT ID: NCT04180501 Recruiting - Brain Metastases Clinical Trials

SRS Sequential Sindilimab in Brain Metastasis of NSLSC

Start date: November 2019
Phase: Phase 2
Study type: Interventional

A phase II study on the treatment of advanced non-small cell lung cancer with brain metastasis by SRS sequential sintilimab